A presentation on thimerosal, a mercury-based vaccine preservative, set to be delivered to the CDC’s advisory committee has come under scrutiny for referencing a non-existent study. The report, “Thimerosal as a Vaccine Preservative,” authored by Lyn Redwood—former leader of the anti-vaccine group Children’s Health Defense—cited a 2008 study allegedly co-authored by UC Davis Professor Emeritus Robert Berman. However, Berman confirmed that such a study was never conducted by him and said the cited findings misrepresented his actual research published in Toxicological Sciences.
The erroneous citation was first reported by Reuters, prompting the CDC to upload a revised version of Redwood’s presentation, removing the disputed slide. The controversy has intensified after Health Secretary Robert F. Kennedy Jr. recently replaced the CDC’s entire 17-member vaccine panel with eight new members, half of whom are known vaccine skeptics.
Both Republican Senator Bill Cassidy and Democratic Senator Patty Murray have urged postponement of the June 25–26 meeting, citing the panel’s lack of vetting and the absence of a CDC director. Redwood’s presentation contrasts with a separate CDC staff report reaffirming that thimerosal-containing vaccines do not cause autism or other neurodevelopmental issues.
According to CDC data, 96% of flu vaccines administered during the 2024–25 season were thimerosal-free, and only 0.3% of flu vaccines given to pregnant women contained the preservative. Kennedy, a long-time critic of vaccine safety, has previously claimed thimerosal causes brain damage—claims consistently debunked by scientific research.
The thimerosal debate highlights rising tensions around vaccine policy and misinformation, especially as newly appointed CDC advisors consider whether to recommend thimerosal-free vaccines for all pregnant women and children. Redwood has not yet responded to requests for comment.


Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
U.S.-Iran Nuclear Talks Show Progress but No Breakthrough Amid Rising Military Tensions
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Maduro Seeks Dismissal of U.S. Drug Trafficking Case, Citing Sanctions Interference
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
UN Rapporteur Francesca Albanese Condemns “Toxic” Attacks Amid Calls for Resignation
FBI Subpoenaed Kash Patel and Susie Wiles Phone Records During Trump Investigations, Patel Says
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



